Table 1 Participants characteristics
Cohort, No. (%) | |||
|---|---|---|---|
Variable | Training (n = 208) | Validation (n = 88) | P Value |
Median age, yr (IQR) | 72.0 (12.0) | 72.0 (11.2) | 0.917 |
Median PSA, ng/ml (IQR) | 12.0 (13.5) | 10.1 (11.7) | 0.844 |
Median prostate volume, cm3, (IQR) | 39.5 (26.4) | 37.0 (28.3) | 0.497 |
Median PSAD, ng/ml/cm3, (IQR) | 0.3 (0.4) | 0.3 (0.3) | 0.171 |
The median maximum diameter of lesion, cm (IQR) | 19.6 (8.2) | 19.5 (5.7) | 0.059 |
Median area of lesion, mm2 (IQR) | 232.0 (162.2) | 251.0 (154.8) | 0.674 |
Zonality of lesion, n(%) | |||
Peripheral zone | 94 (45.2) | 34 (38.6) | 0.040 |
Transition zone | 96 (46.2) | 52 (59.1) | |
Peripheral zone and transition zone | 18 (8.7) | 2 (2.3) | |
Outcome | |||
Clinically significant prostate cancer | 132 (63.5) | 56 (63.6) | 1.000 |
Benign and clinically insignificant prostate cancer | 76 (36.5) | 32 (36.4) | |
ISUP Grade, n(%) | |||
0 (benign) | 40(21.6) | 16(20.5) | 0.756 |
1 | 36(15.9) | 16(17.0) | |
2 | 49(22.6) | 25(27.3) | |
3 | 41(19.7) | 18(20.5) | |
4 | 37(17.8) | 10(11.4) | |
5 | 5(2.4) | 3(3.4) | |
Median ADCmin (IQR) | 433.5 (252.8) | 448.5 (200.5) | 0.224 |
Median ADCmean (IQR) | 661.0 (250.8) | 669.0 (234.0) | 0.792 |
Median ADCminr (IQR) | 0.5 (0.3) | 0.5 (0.2) | 0.556 |
Median ADCmeanr (IQR) | 0.5 (0.2) | 0.5 (0.2) | 0.077 |